Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01439347

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Acute Lymphoblastic Leukemia (ALL) Clinical Trial

Official title:
Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Clinical Trial Summary

A phase 3 study in the treatment of subjects >or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

Clinical Trial Description

A phase 3, multicenter, randomized study to evaluate the substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for standard Vincristine Sulfate Injection (VSI) in the induction, intensification, and maintenance phases of combination chemotherapy in the treatment of subjects >or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01439347
Study type Interventional
Source Spectrum Pharmaceuticals, Inc
Contact
Status Terminated
Phase Phase 3
Start date March 2012
Completion date November 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03590171 - International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Phase 2
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Recruiting NCT01351545 - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting NCT02894645 - Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Phase 4
Completed NCT03236857 - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Phase 1
Completed NCT03181126 - A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Phase 1
Recruiting NCT05291390 - Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Completed NCT01221857 - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT01282593 - Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9). N/A
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Completed NCT03067584 - Genetic Study of Familial Acute Lymphoblastic Leukemia
Recruiting NCT05884333 - Cord Blood Transplant in Adults With Blood Cancers Phase 2
Terminated NCT02338050 - Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT01802814 - International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 Phase 3
Completed NCT00495079 - Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia Phase 2
Completed NCT01735955 - Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study Phase 4
Recruiting NCT04929899 - Bright Ideas - CIN Feasibility Study N/A
Active, not recruiting NCT02061800 - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Phase 1/Phase 2
Terminated NCT01050764 - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Phase 1/Phase 2